Ariel Investments reported a strong Q2 performance for its International Developed Markets Composite, which rose 22.61% gross of fees, outperforming MSCI EAFE benchmarks. Key contributors included Murata Manufacturing, benefiting from AI data center demand, and Infineon Technologies, which raised guidance on revenue and margin growth. Additionally, Ariel invested in Pharmaron Beijing, anticipating growth from China's expanding biopharma sector. BT's shift from peak investment to cost efficiencies also supported cash flow improvements, highlighting a strategic portfolio adjustment toward technology and innovation sectors.
RENK Group AG reported a record €1.2 billion in orders for the first half of 2026, a 29.7% increase from the previous year, driven by strong demand in defense. The company achieved its highest-ever quarterly order intake of €612.8 million in Q2, with...
RENK Group AG reported a record order intake of around €1.2 billion in the first half of 2026, a 29.7% increase from the previous year, driven by strong demand in defense. Revenue rose slightly by 2.7% to €637.2 million, while adjusted EBIT grew by 1...
Mowi ASA will present its second quarter 2026 financial results on August 18, 2026, at 08:00 CET in Oslo, Norway. The presentation will be conducted in English and streamed live online, followed by a Q&A session allowing participants to submit questi...
GCL Global Holdings Ltd. announced it will propose to adjourn its Extraordinary General Meeting scheduled for August 7, 2026, to December 1, 2026. The company is reassessing its compliance with Nasdaq listing requirements and believes the planned sha...
Evotec SE has entered a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases. The partnership leverages Evotec's AI-driven discovery platform, advanced screening, and proprietary co...
